Anixa Biosciences, Inc.

NasdaqCM:ANIX Stock Report

Market Cap: US$106.8m

Anixa Biosciences Management

Management criteria checks 2/4

Anixa Biosciences' CEO is Amit Kumar, appointed in Jul 2017, has a tenure of 7.33 years. total yearly compensation is $3.64M, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. directly owns 1.61% of the company’s shares, worth $1.72M. The average tenure of the management team and the board of directors is 7.7 years and 6.1 years respectively.

Key information

Amit Kumar

Chief executive officer

US$3.6m

Total compensation

CEO salary percentage19.8%
CEO tenure7.3yrs
CEO ownership1.6%
Management average tenure7.7yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Sep 12
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

May 23
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Jan 19
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27
Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28
Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12
Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

CEO Compensation Analysis

How has Amit Kumar's remuneration changed compared to Anixa Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jul 31 2024n/an/a

-US$12m

Apr 30 2024n/an/a

-US$12m

Jan 31 2024n/an/a

-US$11m

Oct 31 2023US$4mUS$720k

-US$10m

Jul 31 2023n/an/a

-US$11m

Apr 30 2023n/an/a

-US$11m

Jan 31 2023n/an/a

-US$12m

Oct 31 2022US$2mUS$631k

-US$14m

Jul 31 2022n/an/a

-US$14m

Apr 30 2022n/an/a

-US$16m

Jan 31 2022n/an/a

-US$15m

Oct 31 2021US$11mUS$573k

-US$13m

Jul 31 2021n/an/a

-US$11m

Apr 30 2021n/an/a

-US$9m

Jan 31 2021n/an/a

-US$10m

Oct 31 2020US$2mUS$522k

-US$10m

Jul 31 2020n/an/a

-US$10m

Apr 30 2020n/an/a

-US$9m

Jan 31 2020n/an/a

-US$9m

Oct 31 2019US$665kUS$476k

-US$12m

Jul 31 2019n/an/a

-US$15m

Apr 30 2019n/an/a

-US$18m

Jan 31 2019n/an/a

-US$17m

Oct 31 2018US$12mUS$425k

-US$14m

Compensation vs Market: Amit's total compensation ($USD3.64M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Amit's compensation has increased whilst the company is unprofitable.


CEO

Amit Kumar (60 yo)

7.3yrs

Tenure

US$3,639,651

Compensation

Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...


Leadership Team

NamePositionTenureCompensationOwnership
Amit Kumar
CEO, Chairman & Co-Chair of CBAB7.3yrsUS$3.64m1.61%
$ 1.7m
Michael Catelani
President8yrsUS$1.97m0.11%
$ 116.9k
John Roop
Senior Vice President of Engineering12.2yrsUS$275.00kno data
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board3.2yrsno datano data

7.7yrs

Average Tenure

64.5yo

Average Age

Experienced Management: ANIX's management team is seasoned and experienced (7.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Amit Kumar
CEO, Chairman & Co-Chair of CBAB12yrsUS$3.64m1.61%
$ 1.7m
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board1.8yrsno datano data
Lewis Titterton
Lead Independent Director7.3yrsUS$169.35k2.84%
$ 3.0m
H. Shepard
Member of Scientific Advisory Boardno datano datano data
Linda Kelley
Member of Scientific Advisory Board6.1yrsno datano data
Ian Frazer
Member of Scientific Advisory Board5.1yrsno datano data
G. Budd
Member of Breast Cancer Clinical Advisory Board1.8yrsno datano data
Arnold Baskies
Member of SAB & Breast Cancer Clinical Advisory Board6.2yrsUS$169.35k0.36%
$ 381.8k
Marco Davila
Member of Scientific Advisory Board6.1yrsno datano data
Jose Conejo-Garcia
Member of Scientific Advisory Board6.1yrsno datano data
Daniel Abate-Daga
Member of Scientific Advisory Board6.1yrsno datano data
Emily Gottschalk
Independent Director5.1yrsUS$169.35k0.14%
$ 151.6k

6.1yrs

Average Tenure

70yo

Average Age

Experienced Board: ANIX's board of directors are considered experienced (6.1 years average tenure).